Mega Genomics Ltd. has announced a delay in the publication of its 2024 Annual Results and the associated Annual Report. The company, listed on the Hong Kong Stock Exchange, stated that the delay is due to ongoing discussions with a potential new auditor. Trading in the company's shares has been suspended since April 1, 2025, and will remain so until further notice. The company aims to dispatch the necessary Circular to shareholders as soon as practicable.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.